With baby KJ successfully receiving the world’s first personalized CRISPR therapy, alongside continued innovation across in vivo and base editing, and rapid ex vivo clinical progress, the genome editing field […]

As 2025 shapes up to be a transformative year for talent acquisition in life sciences, the 7th LEAP TA: Life Sciences returns to Boston, MA this September (29 - October 1), […]

The 9th MASH Drug Development Summit is the definitive meeting for pharma and biotech leaders advancing the next generation of therapies for MASH. With the approval of Rezdiffra signaling a […]

Unlock the future of cell and gene therapy manufacturing at the 2nd Raw Materials for Cell & Gene Therapy Summit. This is your exclusive opportunity to hear directly from regulatory […]

Driving Analytical Excellence from Pre-IND Through BLA for Next-Generation Gene Therapies Returning to Boston this October, the 7th Gene Therapy Analytical Development Summit is the industry’s definitive meeting for advancing […]

The 3rd Spatial Biology for Drug Development Summit is your opportunity to come together with leading biopharma experts to address these challenges within the spatial biology space head-on. Across an […]

With CMS introducing new guidance for RWD studies, the FDA announcing a new RWE Center, and RWD becoming more accessible, it is clear that RWE will play an increasingly pivotal […]

 Returning as the industry’s definitive forum from early discovery to clinical development, the 8th Annual TPD & Induced Proximity Summit is the world’s largest and longest-standing forum for proximity-based modalities, enabling you […]

The rare disease trial landscape stands at a pivotal tipping point. While unprecedented advances in trial design, digital tools, and regulatory flexibility are accelerating innovation like never before, the reality […]

Funding pressures, regulatory shifts, global competition, and relentless layoffs are redefining the pre-commercial biopharma landscape. In this climate, agile, transparent, and people-first leadership is critical to keeping teams engaged, culture […]

Industry’s Flagship Forum Capturing Advancements Across Discovery, Preclinical, Translational, Clinical & Regulatory Development of Innovative Neuropsychiatric Therapeutics Uniting 150+ discovery, preclinical, translational, clinical, and regulatory leaders, the 8th Neuropsychiatric Drug Development Summit returns to provide you […]

Have you considered how microneedle drug delivery systems could revolutionise the future of vaccine and drug administration? This November, join SAE Media’s 4th Annual Transdermal and Microneedle Drug Delivery Conference. […]

7th Targeted Radiopharmaceuticals Summit Europe 10–12 November 2025 | Amsterdam Translating Novel Radiopharmaceutical Therapies to Transform the Medical Future Now in its seventh year, the Targeted Radiopharmaceuticals Summit Europe returns […]

Now in its seventh year, the TIL Therapies Summit returns as the leading event dedicated to advancing tumor-infiltrating lymphocytes (TIL) therapies. Taking place November 11–13, 2025, in Boston (MA), this […]

2025 has seen a wave of positive anti-fibrosis advances. From Agomab’s Phase 2a results in fibrostenosing Crohn’s, Boehringer’s Phase 3 IPF data, Stanford’s TGF-β work in cardiovascular fibrosis, to over […]

With the release of the draft ICH M15 guidelines and the FDA’s move to phase out animal testing, regulatory change is accelerating, solidifying Model-Informed Drug Development (MIDD) as a critical, […]

3rd LNP Characterization & Analytical Development Summit De-Risk Regulatory Submissions Through Smarter LNP Characterization Curated in collaboration with leading analytical scientists and key LNP stakeholders, the 3rd LNP Characterization & […]

The Only Industry-Dedicated Summit for Advancing Myeloid Cell Therapies in Oncology, Inflammation and Beyond... Uniting leading experts from pharma, biotech, and academia, the 7th Myeloid-Directed Therapies Summit is the definitive […]

The 9th Dermatology Drug Development Summit is the definitive industry-led forum bringing together a driven community of experts pioneering innovative drug discovery and clinical strategies to improve long-term outcomes for patients with […]

Returning for its third year, the Donor Selection & Cell Source Summit is the only industry-dedicated forum focused exclusively on the strategic and scientific challenges of donor selection and cell […]

Diving Into the Complement Cascade to Explore Intervention Points, Harnessing Biomarker Strategies to Identify Optimal Patient Populations, & Exploring the Therapeutic Opportunity from Rare Disease to Inflammation to Autoimmune Disease. […]

Recognized as the industry’s leading forum for cell therapy analytical, quality control, assay, and CMC professionals, the 7th Cell Therapy Analytical Development Summit, returns to Boston to provide the expertise […]

RNA-targeting small molecules are rapidly emerging as a powerful therapeutic reality. From modulating splicing to directly binding RNAs, these molecules offer a revolutionary approach to treating previously undruggable diseases across […]

The 2nd Innovation in Obesity Therapeutics Summit will return to San Diego this December. Hear from the titans of the pharmaceutical industry, including Novo Nordisk, Eli Lilly and Boehringer Ingelheim, […]

With major FDA changes already reshaping the regulatory landscape - and global agencies ramping up scrutiny - 2025 is a pivotal year for cell and gene therapy regulatory professionals. With […]

The World’s Only Industry-Specific Forum on AI-Oriented Skills-Centric Workforce Transformation in Life Sciences Most roles in biopharma organizations will undergo an AI-driven transformation in the coming years. But exactly how […]

Navigate New FDA Leadership, Harness AI-Powered Submissions & Align Technical Innovation with the Latest Nonclinical, Clinical & CMC Guidance to Overcome Regulatory Challenges and Accelerate Your Path to Clinic & […]

The 6th Gene Therapy for Ophthalmic Disorders Summit returns to Raleigh, North Carolina, as the leading industry forum dedicated to accelerating the development of gene therapies for both rare and common eye […]

Ever since the field-defining studies in Nature Medicine and the New England Journal demonstrated that cell therapies could hold lasting potential in lupus and beyond, the field has grown from […]

With the European oncology market increasingly focused on emerging modalities, highlighted by AbbVie’s recent licensing agreement with Ichnos Glenmark Innovation for their trispecific antibody, Boehringer Ingelheim’s partnership with Tempus to advance their cancer pipeline […]